Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study

Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin‐2, a hormone with vasodilatory and end‐organ protective effects believed to play a central role in the car...

Descripción completa

Detalles Bibliográficos
Autores principales: Teerlink, John R., Voors, Adriaan A., Ponikowski, Piotr, Pang, Peter S., Greenberg, Barry H., Filippatos, Gerasimos, Felker, G. Michael, Davison, Beth A., Cotter, Gad, Gimpelewicz, Claudio, Boer‐Martins, Leandro, Wernsing, Margaret, Hua, Tsushung A., Severin, Thomas, Metra, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2017
Materias:
Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488179/
https://www.ncbi.nlm.nih.gov/pubmed/28452195
http://dx.doi.org/10.1002/ejhf.830

Ejemplares similares

Ejemplares similares